Navigation Links
Bradmer to participate in panel presentation at RBC Capital Markets Healthcare Conference
Date:12/9/2008

TSX: BMR

TORONTO, Dec. 9 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that Alan M. Ezrin, Ph.D., President and Chief Executive Officer of Bradmer will be presenting as a panel participant at the 2008 RBC Capital Markets Healthcare Conference, held at the Westin Times Square Hotel in New York City. The panel titled, Antibody Strategies For Fighting Cancer, is scheduled from 3:30 pm to 4:25 pm (Eastern Time) on December 10, 2008 in Panel Room 2. Interested parties can access a live audio webcast of the panel by visiting Bradmer's website at www.bradmerpharma.com. The webcast will be available for 30 days after the conference.

About Bradmer Pharmaceuticals Inc. (www.bradmerpharma.com)

Bradmer Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new and innovative cancer therapies. Bradmer's lead clinical candidate, Neuradiab(R), was developed at Duke University Medical Center as a proprietary therapy for a particularly aggressive form of brain cancer, glioblastoma multiforme. Bradmer has initiated enrollment in a Phase III multi-center clinical trial of the licensed treatment. Neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administration and the European Medicines Agency.

Bradmer Pharmaceuticals Inc.'s common shares have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state regulatory agency in the United States. The resale or transfer by a U.S. investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of Regulation S of the Securities Act or such other applicable exemp
'/>"/>

SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Bradmer announces management changes
2. Bradmer provides Phase III Neuradiab trial update and guidance
3. Bradmer to present at Rodman & Renshaw Healthcare Conference
4. Bradmer Medical Isotope Supply For Phase III Trial Secure
5. Bradmer announces additions to Scientific Advisory Board
6. Bradmer to present at the 10th Annual BIO CEO & Investor Conference
7. Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study
8. Notice of Bradmer Pharmaceuticals Conference Call
9. Bradmer announces 2007 fourth quarter and fiscal year operational and financial results
10. Bradmer announces new additions to management team
11. Bradmer announces 2008 first quarter operational and financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/20/2014)... (PRWEB) December 20, 2014 Developers of ... release of a new plugin for Final Cut Pro ... , “TranSlice Volume 5 allows users to create hand ... it.” Said Christina Austin, CEO of Pixel Film Studios. ... of professionalism while maintaining an easy to use interface.” ...
(Date:12/20/2014)... December 20, 2014 Today, Balfleet.com, one ... a Christmas Sale, offering 50%-70% off on its ... season. , The mother of the bride dresses from ... company is 24/7 accessible and takes pride in providing ... , “We are offering great discounts on our mother ...
(Date:12/19/2014)... Sub Zero Ice Cream is partnering up with ... the 28th from 2pm-6pm at the Expo Center on the ... FL. , Inquiries regarding time slots and signing up, email ... donating process, Sub Zero Ice Cream & Yogurt will be ... , About Sub Zero Ice Cream & Yogurt , ...
(Date:12/19/2014)... CA (PRWEB) December 19, 2014 SuperCloset ... 5x5 SuperClone Rooms. SuperCloset continues to offer indoor growers ... Pair one of the new SuperClone Rooms with the ... perpetual, and turnkey indoor hydroponic grow room setup. , ... the world, SuperCloset’s SuperPonic SuperCloner 50 . ...
(Date:12/19/2014)... TX (PRWEB) December 20, 2014 The ... a new injectable filler from respected cosmetic brand Juvéderm. ... occur naturally with age. The Medspa at Hendrick is ... development in skin care technology to its clients. , ... gel to be FDA-approved to treat the mid-face and ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2Health News:Balfleet.com is Offering 50%-70% Off of its Mother of the Bride Dresses 2Health News:Shark Tank’s Sub Zero Ice Cream Sponsors Blood Drive 2Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2
... Greater International Representation, WASHINGTON, Aug. 12 ... participation of 37 Supporting Partner,Organizations from around ... Zealand, Russia and the United Kingdom, as ... in the U.S. These Supporting Partner,Organizations have ...
... Investment Trust Inc.,(NYSE: CRE ) ("Care"), a real ... and commercial mortgage debt,today announced an agreement in principle ... terms:, -- Care will receive an option to ... mortgage assets on an individual basis at any time ...
... The development and repair of heart tissue and blood ... ribonucleic acid (RNA) that is found nowhere else in ... found. , Because of its specificity to the cardiovascular ... therapeutic treatment, the researchers said. , "Manipulating this microRNA ...
... N.J., Aug. 12 Barr Pharmaceuticals,Inc. (NYSE: ... Barr Laboratories subsidiary has,signed a Settlement Agreement ... resolve the patent litigation involving Boehringer Ingelheim,s,Mirapex(R) ... Settlement,Agreement and a Supply Agreement to resolve ...
... the release of Sfetyworks™, a web-based, semi-automated ... quickly spot and measure the strength of ... condition found within large electronic healthcare databases. ... plc (GSK) and ProSanos. Several years in ...
... Ind., Aug. 12 Hillenbrand, Inc.,(NYSE: HI ... consistent,with $165.6 million reported in the third quarter ... third-quarter earnings per share, operating,profit and cash flow ... for the quarter remained essentially flat, even as ...
Cached Medicine News:Health News:AdvaMed 2008 Supporting Partner Organizations Up 30% Over Last Year 2Health News:AdvaMed 2008 Supporting Partner Organizations Up 30% Over Last Year 3Health News:AdvaMed 2008 Supporting Partner Organizations Up 30% Over Last Year 4Health News:Care Investment Trust Inc. Announces an Agreement in Principle for CIT Healthcare to Purchase Mortgage Assets and Reduce Management Fee 2Health News:Tiny molecule helps control blood-vessel development, UT Southwestern researchers find 2Health News:Barr Announces Agreements to Settle Mirapex(R) and Aggrenox(R) Patent Challenges 2Health News:Barr Announces Agreements to Settle Mirapex(R) and Aggrenox(R) Patent Challenges 3Health News:Barr Announces Agreements to Settle Mirapex(R) and Aggrenox(R) Patent Challenges 4Health News:Barr Announces Agreements to Settle Mirapex(R) and Aggrenox(R) Patent Challenges 5Health News: ProSanos Corporation Releases New Software System to Improve Patient Safety via Surveillance and Analysis of Claims and Electronic Health Records 2Health News:Hillenbrand, Inc. Reports Third-Quarter Revenue of $165 Million and Earnings Per Share of $0.42 2Health News:Hillenbrand, Inc. Reports Third-Quarter Revenue of $165 Million and Earnings Per Share of $0.42 3Health News:Hillenbrand, Inc. Reports Third-Quarter Revenue of $165 Million and Earnings Per Share of $0.42 4Health News:Hillenbrand, Inc. Reports Third-Quarter Revenue of $165 Million and Earnings Per Share of $0.42 5Health News:Hillenbrand, Inc. Reports Third-Quarter Revenue of $165 Million and Earnings Per Share of $0.42 6Health News:Hillenbrand, Inc. Reports Third-Quarter Revenue of $165 Million and Earnings Per Share of $0.42 7Health News:Hillenbrand, Inc. Reports Third-Quarter Revenue of $165 Million and Earnings Per Share of $0.42 8Health News:Hillenbrand, Inc. Reports Third-Quarter Revenue of $165 Million and Earnings Per Share of $0.42 9
(Date:12/19/2014)... Kan. , Dec. 18, 2014   ... ), a biopharmaceutical company focused on the licensing, ... animals, today announced positive results from its pivotal ... drug for treating pain in dogs with osteoarthritis. ... in pain assessment scores that were statistically significant ...
(Date:12/17/2014)... , Alemania, December 17, 2014 ... año anterior, con un alto nivel de gasto en ... año fiscal 2013/14 (finalizado el 30 de septiembre de ... ciento a 4.287 millones de euros (año anterior: 4.190 ... la moneda desfavorables. Las ganancias (EBIT) crecieron un 14 ...
(Date:12/17/2014)... 17, 2014 With advancements in neurological ... market is seeing new growth, according to Kalorama ... account for the majority of market volume, newer ... images, which are creating opportunities for more sophisticated applications. ... growing at a rate of 4%, with world ...
Breaking Medicine Technology:Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS confirma su posición en un entorno difícil 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3
... Optimal for Subcellular Fractionation, ... x g (30,000 rpm) with ... from 0.25 up to 85 ... 2° C to 40° C ...
... for Subcellular Fractionation, Proteins and ... (30,000 rpm) with fixed-angle rotor ... up to 85 mL • ... to 40° C • Rotors ...
... to accommodate over 55 centrifuge tubes, bottles, ... labile samples. Incorporating the latest technology, these ... quick cooling from 22 C to 4 ... brushless motor, low pitch 62 dBA quiet ...
... hold 16 0.2ml tubes. Easy operation (no ... polycarbonate lid to start and press the ... in seconds. Maximum centrifuge speed 6400 rpm ... in diameter. Also available in 220v/50hz.; 220v ...
Medicine Products: